Company: PRME
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001193125-25-122156
Chunk: 4

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.02
Chunk 4
---
 the date of grant and will vest upon the achievement of agreed milestones that will be set forth in the applicable equity agreement, subject to Dr. Reine’s continuous service.

Dr. Reine has also entered into the Company’s standard form of director indemnification agreement, which was filed as Exhibit 10.7 to the Company’s Registration Statement on Form S-1/Afiled on October 17, 2022.

There is no arrangement or understanding between Dr. Reine and any other person pursuant to which he was selected as an officer and director of the Company, and there are no family relationships between Dr. Reine and any of the Company’s directors or executive officers. There are no transactions to which the Company is a party and in which Dr. Reine has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K. Dr. Reine’s biography is set forth in the Company’s definitive proxy statement for its 2025 annual meeting of stockholders filed pursuant to Regulation 14A on April 22, 2025.

The foregoing summary of the Reine Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Reine Employment Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form10-Qfor the quarter ending June 30, 2025.

  Item 7.01      Regulation FD Disclosure.  

On May 19, 2025, the Company issued press releases titled “ Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease” and “ Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition.” A copy of each press release is furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form8-K, which is incorporated herein by reference.

On May 19, 2025, the Company posted an updated corporate presentation to its website at https://investors. primemedicine. com/news-events. A copy of the corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form8-K, which is incorporated herein by reference. Reference to the Company’s website is for inactive textual reference only and the content of the website should not